Naslov
RELATIONSHIP BETWEEN CONTROLLED ATTENUATION PARAMETER AND LIVER STIFFNESS MEASUREMENTS OBTAINED BY FIBROSCAN® WITH RED BLOOD CELL DISTRIBUTION WIDTH IN PATIENTS WITH ONE OR MORE COMPONENTS OF METABOLIC SYNDROME

Autori
Mikolašević, Ivana ; Orlić, Lidija ; Štimac, Davor ; Krišto, Nikolina ; Jakopčić, Ivan ; Mavrinac, Vojko ; Milić, Sandra

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
Clinical hepatology practice in 2016: from science to therapy

Mjesto i datum
Birmingham, Ujedinjeno Kraljevstvo, 02.09.2016. - 03.09.2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Controlled Attenuation Parameter; liver stiffness measurements; red blood cell distribution width

Sažetak
AIM: Our aim was to investigate the correlation between Controlled Attenuation Parameter (CAP) and liver stiffness measurements (LSM) values obtained by FibroScan® as measurements of liver steatosis/fibrosis and red blood cell distribution width (RWD) values in patients with one or more components of metabolic syndrome (MS). MATERIALS AND METHODS: In this prospective study we have analyzed 360 patients between April 2014 and October 2015. The HIS, FIB-4 and BARD scores as well as CAP and LSM were obtained to asses liver steatosis and fibrosis. RESULTS: RDW showed significant positive correlation with age, presence of diabetes, hypertension and MS, waist circumference, CRP and uric acid as well as with LSM, HIS and BARD scores as indicators of fibrosis (all p<0.05). Patients with higher RDW values (>13.4%), had statistically significantly higher incidence of diabetes, hypertension, MS, higher values of waist circumference. CRP, uric acid, as well as CAP, LSM and FIB-4 and BARD scores in comparison to the patients with lower RDW (≤13.4%) values. In multivariate analysis, RDW continued to be statistically significant and an independent predictor of elevated LSM (OR = 1.88, 95%CI: 1.0226-3.4774, p =0.04) CONCLUSION: RDW, is an inexpensive, non-invasive parameter that can be used for assessment of liver steatosis/fibrosis in NAFLD patients, especially in those with MS. Our results give a possibility that RDW in combination with FibroScan®-CAP or in combination with some other noninvasive markers could identify patients with NAFLD that have a risk for progression of liver disease.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA